After a difficult 2023, biopharma investors won't necessarily have it any easier in 2024, analysts at UBS argued in a note to clients on Tuesday.  “BioPharma investors will be happy to shut the doo...

Early data points to Lilly's weight-loss drug Zepbound taking market share away from Ozempic and Wegovy. However, Novo Nordisk could still top Lilly in sales gains this year.

Eli Lilly's valuation sets a high bar for the stock. Its rival in the obesity space is a better deal and could be a better business.

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company...

The company's early Alzheimer's treatment, donanemab, may soon obtain approval from regulators. It has the potential to generate billions in revenue and may act as another growth catalyst for Lilly.

Soaring sales of diabetes drug Mounjaro made 2023 a great year to own Eli Lilly stock. Peak annual sales of recently-approved weight-management drug Zepbound (which has the same active ingredient a...

Ken Griffin is the founder, CEO and majority owner of Citadel, one of the premier hedge funds. Griffin founded the company in 1990 and grew it into what it is today through a combination of quantit...

The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close.

Eli Lilly could earn an important approval in 2024. The company's financial results could improve, too.

The latest trading day saw Eli Lilly (LLY) settling at $572, representing a +0.31% change from its previous close.

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Eli Lilly's sales growth should accelerate next year now that Zepbound has obtained approval. PDD Holdings owns Temu, which is one of the most popular e-commerce sites in the world today.

Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.

Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.